Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 7,631

Document Document Title
WO/2024/104268A1
The present invention relates to a co-crystal of elacestrant (hereinafter referred to as "compound (I)") dihydrochloride and a preparation method therefor, a pharmaceutical composition comprising the co-crystal, and a use of the co-cryst...  
WO/2024/105007A1
The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer tautomer or N-oxide thereof, ...  
WO/2024/100405A1
The present invention relates to the field of catalytic hydrogenation and, more particularly, to methods of manganese-catalysed asymmetric hydrogenation of prochiral ketimine moieties to chiral amines.  
WO/2024/096117A1
Provided are: a carbon dioxide absorbing/releasing liquid that has high carbon dioxide absorbing performance and high carbon dioxide releasing performance at low temperature, and that is less likely to degrade when absorbing and releasin...  
WO/2024/090919A1
The present invention provides an improved process for preparing a dimethyl-2,3-dihydro-1H-indene derivative or a pharmaceutically acceptable salt thereof. And, the present invention provides novel intermediates useful for the process. W...  
WO/2024/091523A1
The present disclosure relates in some aspects to certain phenethylamine analogs, such as benzocyclobutene and benzocyclopentene analogs, including those of Formula (1). Also provided are methods of synthesizing the compounds, compositio...  
WO/2024/085046A1
The present invention provides a carbon dioxide adsorbent that allows efficient use of an amine compound supported thereon and allows efficient recovery of carbon dioxide. The carbon dioxide adsorbent according to the present invention c...  
WO/2024/084517A1
This invention provides a group of novel L-amino acid esters substituted 3-phenyl- 3-(aryloxy)propan-1-amine derivatives of the following structural Formula I, wherein, the groups R1, R2 and R3 are defined in the specification having ant...  
WO/2023/240156A9
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.  
WO/2024/070946A1
The present invention provides a composition for semiconductor devices which has the excellent ability to remove dry-etching residues and is more inhibited from causing the dissolution of tungsten and which, when works are treated therew...  
WO/2024/059090A1
The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are prov...  
WO/2024/059017A2
The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are prov...  
WO/2024/042952A1
The present invention provides: an acid generator which exhibits excellent solubility in a cationically curable compound; and a curable composition which is rapidly cured when subjected to a heat treatment, and which forms a cured produc...  
WO/2024/040358A1
The present disclosure is generally directed to the extraction of active compounds from plant biomass. In particular, the present disclosure is directed to the extraction of active compounds from plant biomass using solvents of different...  
WO/2024/042951A1
Provided is an acid generator that has superior solubility in cation-curable compounds. This acid generator includes: a salt (1) of a cation represented by formula (c-1) and a monovalent counter anion; and a salt (2) of a cation repres...  
WO/2024/022263A1
A lipid compound and a lipid nanoparticle composition. The lipid compound has a structure represented by formula (I), and can be used in combination with other lipid components, such as neutral lipids, cholesterol, and polymer-conjugated...  
WO/2024/006226A1
Provided are N-substituted phenylalkylamines, methods of making the same, and methods of using such compounds, for example, as receptor probes, as modulators of neurotransmission, and as therapeutic agents, for example as CNS agents. Als...  
WO/2023/241140A1
The present invention relates to the technical field of biological medicine, particularly to use of a class of substituted diaryl compounds in the preparation of anti-inflammatory drugs. The compounds have a structure represented by form...  
WO/2023/244200A1
The invention is a method of obtaining R-propranolol HC1 in enantiomeric purity by microbial stereoinversion method using Rhizopus oryzae CBS 111718 microorganism as the enzyme source from the racemic mixture of propranolol HC1, which is...  
WO/2023/230649A1
The present disclosure relates to compounds of formula (I), their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.  
WO/2023/227029A1
The present invention relates to a novel crystal form of elacestrant (hereinafter referred to as "compound I") dihydrochloride, a preparation method therefor, a pharmaceutical composition containing the crystal form, and uses of the crys...  
WO/2023/229295A1
The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclo...  
WO/2023/209033A1
In one aspect, the present invention relates to a method for crystallizing (2R,3R)-3-(3- methoxyphenyl)-N,N,2-trimethylpentan-1-amine or salts thereof (compound I), the method comprising the following steps: (i) mixing compound I with a ...  
WO/2023/202554A1
Disclosed are a chiral aryl propionic acid derivative and a pharmaceutical composition thereof, and a use. The chiral aryl propionic acid derivative is as shown in formula (I), and the definition of each group is given in the description...  
WO/2023/200015A1
The present invention provides: iron phosphide nanoparticles which are stable in the atmosphere, and in which iron atoms are in a low valence state; a method for producing the iron phosphide nanoparticles; and a reduction catalyst. The p...  
WO/2023/194382A1
Disclosed herein is a salt of formula (I): wherein q is + or –; p is 2+, +, – or 2–; g is 1 or 2; G is selected from R5-C≡C-CO2 –, R5- C≡C-C(=O)S–, R5-C≡C-CS2 –, R5-C≡C-SO2 –, R5-C≡C-S(=O)S–, R5-C≡C-SO3 –, R...  
WO/2023/176209A1
A tosylic acid anionic ionic liquid represented by formula (1) is a unique compound that is especially stable in supercooled conditions and maintains a liquid state especially easily, even among ionic liquids, and can be handled as a liq...  
WO/2023/168484A1
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)  
WO/2023/171694A1
Provided in an embodiment is a core-shell type heterogeneous catalyst provided with a core 1 and a shell 2 positioned on the outside of the core 1, wherein the shell 2 contains a metal complex structure 3 containing a Josiphos ligand.  
WO/2023/156450A1
There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, m...  
WO/2023/156453A1
There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and k...  
WO/2023/153504A1
A nucleic acid delivery material containing a perylene-diimide-ring-free polycyclic aromatic compound having one or more primary, secondary, or tertiary amino groups or nitrogen-cation-containing groups has exceptional efficiency in nucl...  
WO/2023/019244A9
Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intoler...  
WO/2023/149559A1
[Problem] The present invention provides a catalyst for hydrogenation reactions, the catalyst having excellent catalyst durability and being capable of selectively hydrogenating only some functional groups and/or unsaturated bonds of an ...  
WO/2023/143600A1
The present invention provides a novel cationic lipid, a lipid nanoparticle, and a nucleic acid vaccine. According to the present invention, a specific cationic lipid is selected to prepare a lipid nanoparticle mRNA vaccine, and the lipi...  
WO/2023/141469A2
Provided are compounds of Formulae (I), (II) and (III) and therapeutic use of the compounds:  
WO/2023/134145A1
The present invention provides a preparation method for a tivozanib key intermediate compound of formula I, 2-chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)-aniline. Compound of formula VI, 4-chloro-6,7-dimethoxyquinoline and compound of for...  
WO/2023/137044A2
Described herein are methods of making (Z)-endoxifen, a salt thereof, crystalline forms of endoxifen, and compositions comprising them. Also described herein are crystalline forms of (Z)-endoxifen. A method of making (Z)-endoxifen may in...  
WO/2023/135035A1
A process for the manufacture of alkanolamines and/or a process for the conversion of al-kanolamines wherein the process is performed in one or equipment items, wherein one or more steel parts of the one or more equipment items, which ha...  
WO/2023/125738A1
Provided are a lipid and a composition used for delivery. Specifically provided is a compound represented by formula I or a salt thereof, wherein R1 to R3, H1 to H3, L1, and L2 are as defined in the description.  
WO/2023/117111A1
The invention relates to an especially recyclable composite material which consists of at least two material layers (1, 4) bonded by a layer (2) of adhesive. For an easy and clean separation of the two material layers the adhesive consis...  
WO/2023/115220A1
A combination comprising tilorone/nelfinavir; tilorone/molnupinavir; tilorone/remdesivir; tilorone/alfacalcidol; tilorone/clofazimine; tilorone/danazol; tilorone/manidipine; tilorone/sertraline; tilorone/trifluoperazine; remdesivir/hexac...  
WO/2023/121753A1
The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, ...  
WO/2023/117112A1
The invention relates to a compound material, especially a recyclable composite material which consists of at least two material layers (1, 2) bonded by a layer (2) of adhesive. For an easy and clean separation of the two material layers...  
WO/2023/122276A1
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...  
WO/2023/118833A1
1. In one aspect, a process for the preparation of vilanterol ((R)-4-(2-((6-(2-((2,6- dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hy droxymethyl)phenol; Compound VI) or a pharmaceutically acceptable salt thereof, comprises ...  
WO/2023/103611A1
The present invention belongs to the field of the synthesis of fine chemical intermediates, and discloses a bromopyrene intermediate and derivatives thereof, a preparation method, and use. The bromopyrene intermediate has a molecular str...  
WO/2023/098203A1
Disclosed in the present invention is a production method for 4,4'-diaminodiphenyl ether, which relates to the technical field of the hydrogenation synthesis of aromatic nitro compounds. According to the production method for 4,4'-diamin...  
WO/2023/102381A1
Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications...  
WO/2023/098622A1
Disclosed are a small molecule binding ligand of a α-synuclein aggregate, and a preparation method therefor and a use thereof. The small molecule binding ligand of a α-synuclein aggregate is a compound shown in the following general fo...  

Matches 1 - 50 out of 7,631